Strong Genetic

Familial Dysautonomia (Riley-Day Syndrome)

Name: Familial Dysautonomia (Riley-Day Syndrome)
Creator: Realised
Published: 2026-03-01

GeneELP1rsIDrs104942231InheritanceAutosomal recessiveCarrier frequency~1 in 30 Ashkenazi Jewish, extremely rare outside this populationSystemCarrier Screening

Summary

Familial dysautonomia is a disorder of the autonomic and sensory nervous systems — the parts of the nervous system that control involuntary functions like blood pressure, heart rate, temperature regulation, digestion, and pain sensation. The ELP1 gene encodes a component of the Elongator complex, which is essential for normal neuronal development. The IVS20+6T>C variant causes tissue-specific exon skipping, resulting in dramatically reduced ELP1 protein in neurons while leaving other cell types less severely affected.

Practical takeaway

This matters when planning children, particularly if your partner is also of Ashkenazi Jewish descent — where the carrier frequency is remarkably high at approximately 1 in 30. This makes familial dysautonomia one of the most common carrier conditions in the Ashkenazi population, comparable in frequency to cystic fibrosis in Northern Europeans. A carrier test through a GP or genetic counselling service can determine your partner's status. If both parents are carriers, a genetic counsellor can discuss the condition's clinical spectrum, the improvements in management and survival, and prenatal testing options. Realised does not calculate reproductive risk or advise on reproductive decisions.

Evidence detail

What Carrier Status Means For You

You are not affected. One working copy of ELP1 produces sufficient protein for entirely normal autonomic and sensory nervous system function. Your carrier status becomes relevant if your partner also carries the ELP1 IVS20+6T>C variant or another rare pathogenic ELP1 variant. In that case, each child has a 25% chance of having familial dysautonomia, a 50% chance of being an unaffected carrier, and a 25% chance of inheriting neither variant.

Population Context

Familial dysautonomia is almost exclusively found in the Ashkenazi Jewish population, where a single founder mutation (IVS20+6T>C) accounts for over 99% of disease alleles. The carrier frequency of ~1 in 30 is among the highest of any serious genetic condition in any population. Only a handful of non-Ashkenazi cases have been reported, involving a different, extremely rare variant. The condition is part of the standard Ashkenazi Jewish carrier panel and was one of the first conditions for which population-based carrier screening was implemented in this community. Screening has significantly reduced birth incidence.

Limitations

23andMe tests 1 ELP1 variant — the IVS20+6T>C founder mutation. For Ashkenazi Jewish individuals, this provides excellent coverage since this single variant accounts for >99% of disease alleles. For non-Ashkenazi individuals, this test has essentially no utility — the extremely rare non-Ashkenazi variant (R696P) is not tested. A "not detected" result in an Ashkenazi individual very substantially reduces but does not completely eliminate carrier risk (a second, much rarer Ashkenazi variant exists). Comprehensive carrier screening through a clinical laboratory may cover additional variants.

Sources (5)

Open in the Library: search, filter, every entry →